Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma. It includes three major subtypes termed germinal center B-cell-like, activated B-cell-like, and primary mediastinal B-cell lymphoma. With the emergence of novel targeted therapies, accurate methods capable of interrogating this cell-of-origin classification should soon become essential in the clinics. To address this issue, we developed a novel gene expression profiling DLBCL classifier based on reverse transcriptase multiplex ligation-dependent probe amplification. This assay simultaneously evaluates the expression of 21 markers, to differentiate primary mediastinal B-cell lymphoma, activated B-cell-like, germinal center B-cell-like, and also Epstein-Barr viruse positive DLBCLs. It was trained using 70 paraffin-embedded biopsies and validated using >160 independent samples. Compared with a reference classification established from Affymetrix U133 þ 2 data, reverse transcriptase multiplex ligationdependent probe amplification classified 85.0% samples into the expected subtype, comparing favorably with current diagnostic methods. This assay also proved to be highly efficient in detecting the MYD88 L265P mutation, even in archival paraffin-embedded tissues. This reliable, rapid, and cost-effective method uses common instruments and reagents and could thus easily be implemented into routine diagnosis workflows, to improve the management of these aggressive tumors.
Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma, accounting for nearly 40% of cases. 1 It is a heterogeneous disease that includes aggressive tumors of different mature B-cell origins. Two molecular subtypes have been identified by gene expression profiling (GEP). 2e4 The first, termed germinal center B-cell-like (GCB), is associated with a gene expression signature of normal germinal center B cells. Its prognosis is usually favorable, with a 5-year overall survival rate of almost 75%. The second, termed activated B-cell-like (ABC), develops from late GC B cells or plasmablasts. These lymphomas are more aggressive, and only 30% of patients can be cured using current therapy regimens. 5 This ABC versus GCB cell-of-origin classification of DLBCLs is now recognized in the World Health Organization classification 6 and should soon have an important impact in the clinics. For example, because ABC DLBCL cell survival strongly depends on B-cell receptor signaling, specific inhibitors of the NF-kB pathway such as ibrutinib appear as promising alternatives to the current immunechemotherapyebased regimens. Similarly, inhibitors of the enhancer of zeste homolog 2 (EZH2), B-cell lymphoma 2 (BCL2), and B-cell lymphoma 6 (BCL6) oncoproteins have shown encouraging results in GCB DLBCL. Accurate diagnostic methods capable of discriminating these subtypes are thus needed. Unfortunately, conventional histology is not informative; array-based GEP, considered the gold standard, is poorly adapted to daily diagnostic work; and the immunohistochemistry (IHC)-based algorithms used in most institutions experience a poor degree of reproducibility. 7, 8 New dedicated GEP methods have thus emerged that show good sensitivity, specificity, and reproducibility, even when applied to formalin-fixed paraffin-embedded (FFPE) biopsies. 9, 10 An important limit of these methods is that they only inform on the GCB and ABC GEP signatures and do not recapitulate the true heterogeneity of these lymphomas. For example, a third important subtype of DLBCL, termed primary mediastinal B-cell lymphoma (PMBL), results from the transformation of thymic B cells. It usually arises in the mediastinum, in younger patients with a female predominance, 11, 12 but recent evidence indicates that it can develop solely at nonmediastinal sites, making its diagnosis challenging. 13 In addition, the recognition of Epstein-Barr virus (EBV)-positive DLBCLs as a definitive entity 6 add further layers of complexity to the diagnosis of these aggressive tumors.
We have recently described a rapid and inexpensive reverse transcriptase multiplex ligation-dependent probe amplification (RT-MLPA) assay that allows for an accurate classification of GCB and ABC DLBCLs. 14 In the present study, we extended this assay to the identification of PMBL, the assessment of the EBV infection status, the detection of the ABC hallmark MYD88 L265P mutation, and to the expression of multiple other prognostic factors and important therapeutic targets.
Materials and Methods
Patients A total of 218 biopsy samples were used in this study ( Supplemental Table S1 ). From the GHEDI (Deciphering the Genetic Heterogeneity of Diffuse large B-cell lymphoma in the rituximab era) study program, fresh/frozen biopsies of 150 DLBCL cases had previously been analyzed using U133 þ 2 GEP arrays (Affymetrix, Santa Clara, CA). The HGU133 þ 2.0 Affymetrix GeneChip microarray data set has been deposited in the National Center for Biotechnology Information's Gene Expression Omnibus (https://www.ncbi.nlm. nih.gov/geo; accession number GSE87371). Fifty-nine samples had been used in validation cohorts for the development of a first GCB-ABC predictor. 14 A total of 38 PMBL cases from the LNH07-3B trial (n Z 9) and from the Center Henri Becquerel, Rouen, France (n Z 29), were also included as well as 30 DLBCL cases from the Center Henri Becquerel. The diagnoses were established according to the World Health Organization 2008 criteria by expert pathologists.
RNA Extraction
For the 150 cases from the GHEDI study and the nine patients from the LNH07-3B trial, RNA samples were extracted from FFPE tissue using Siemens TPS and Versant reagents kit (Siemens Health Care Diagnostics, Erlangen, Germany). For PMBL from the Center Henri Becquerel, RNA was extracted from FFPE tissue for 22 patients using the Maxwell 16 system from Promega (Mannheim, Germany) and from frozen lymph node biopsies for seven patients. RNA from other DLBCLs was extracted from frozen lymph node biopsies when available (n Z 26) and from FFPE tissue using the Maxwell 16 system (n Z 4).
Immunohistochemistry and EBV Infection Status Evaluation
For the samples of the GHEDI cohort, the cell of origin classification was addressed by immunochemistry using the Hans algorithm, by evaluating CD10, BCL6, and melanoma-associated antigen (mutated) 1 (MUM1) expression. 15, 16 Briefly, paraffin-embedded 3-mm-thick sections were subjected to antigen retrieval and antibody staining. The immunoperoxidase stains were performed on a Benchmark Ultra automated stainer (Roche Ventana, Tucson, AZ) using Ultraview Universal diaminobenzidine detection kits. In the absence of an internal positive control, immunostains were considered nonevaluable.
Chromogenic in situ hybridization for EBV-encoded small nuclear early region (EBER-ISH) was performed on FFPE tissue, sectioned at 4 mm, and placed on positively charged slides. Slides with specimens, as well as appropriate positive controls, were then placed in a 60 C oven for 1 hour and loaded onto the Ventana Benchmark XT for subsequent deparaffinization, cell conditioning, enzymatic digestion (Protease 3; Ventana Medical Systems, Tucson, AZ), and in situ staining. The INFORM EBER Probe (Ref 800-2842; Ventana Medical Systems), used in combination with an antiedinitrophenyl-biotin/streptavidin chromogen, was dispensed on the slides and incubated for 60 minutes. The iView Blue Detection Kit (Ventana Medical Systems) was used to produce the chromogenic reaction. Slides were 
All sequences of the RT-MLPA probes and the oligonucleotides used as competitors are provided. The sequences of the primers used for PCR amplification are underlined.
RT-MLPA, reverse transcriptase multiplex ligation-dependent probe amplification.
counterstained using Ventana Medical Systems Red Stain II. After removal from the Benchmark XT, slides were manually dehydrated through graded ethanol solutions and xylene and then a nonaqueous mounting media was used as a coverslip.
Mutational Analysis
Samples from the GHEDI study have been analyzed in a previous study by a dedicated next-generation sequencing Lymphopanel, designed to identify mutations in 34 genes that are important for lymphomagenesis using an Ion Torrent Personal Genome Machine. 17 All MYD88 L265P mutations were confirmed by Sanger sequencing.
RT-MLPA Probes and Reaction Mix
The sequences of the RT-MLPA probes are provided in Table 1 (Eurofins MWG Operon, Ebersberg, Germany). To avoid unwanted amplification of genomic DNA, all gene-specificp a i r s were designed across exoneexon boundaries. All comprised a gene-specific region complementary to the cDNA target and a primer for final PCR amplification. Two probes surrounding the MYD88 L265P mutation were also designed, with the last nucleotide of the 5 0 probe corresponding to the T>C substitution. Finally, two probes were designed to address the expression of the EBER1 transcript. All 5 0 probes have a GTGCCAGCAAGATCCAATCTAGA tail at their 5 0 ends and all 3 0 probes a TCCAACCCTTAGG-GAACCC tail at their 3 0 ends to allow for the final PCR amplification. Spacers of variable lengths were inserted between these primers and the target-specific sequences to allow for distinguishing the different PCR products according to their sizes. All 3 0 probes were phosphorylated at their 5 0 ends to allow the ligation reactions. Competitors identical to one of the probes but without the primers were added to the RT-MLPA probe mix to normalize the amplification signals.
The RT-MLPA probe mix was prepared from 10 mmol/L dilutions of probes and competitors in 10 mmol/L Tris, 1 mmol/L EDTA buffer. The six competitors were first mixed with their corresponding probes at a 1:8 probe-to-competitor ratio for IGHM, 1:6 for IRF4, 1:4 for FOXP1, 1:3 for NEK6, and 1:2 for LMO2 and MS4A1 to normalize the levels of expression. A fixed volume (2 mL) of each probe (n Z 36) or probe þ competitor (n Z 6) dilutions was next mixed to obtain a final volume of 84 mL. An equal volume of 20 mmol/L Tris, 2 mmol/L EDTA solution was then added to obtain a volume of 168 mL. The working solution was obtained by diluting 8.4 mL of this concentrated probe mix in 1 mL of 10 mmol/L Tris, 1 mmol/L EDTA solution.
RT-MLPA Assay and Data Processing
The protocol and data processing were as previously described, 14 using MLPA reagents from MRC-Holland (Amsterdam, The Netherlands). Briefly, 2 mLo ft o t a lR N A from DLBCL biopsies, corresponding to 8 to 500 ng, was added to 3.75 mL of reverse transcription mix containing random hexamer primers. The samples were heated for 1 minute at 80 C to melt the secondary structure, incubated for 5 minutes at 37 C to allow the hybridization of the random primers, and cooled at 4 C. Next, 0.5 mL of Moloney murine leukemia virus reverse transcriptase was added, and the samples were incubated for 15 minutes at 37 C for cDNA synthesis, heated for 2 minutes at 98 C,andcooledat4 C. Then, 3 mL of RT-MLPA probe mix was added (1.5 mLofSALSA-MLPAbufferand1.5mLoffinal dilution probe mix) before denaturation at 95 C for 2 minutes and hybridization at 60 C for 1 hour. Ligation of the annealed oligonucleotides was performed at 54 C for 15 minutes, adding 32 mL of ligation mix, and heated for 5 minutes at 98 C. Next, 2.5 mL of the ligation mixture was added to 7.5 mLofSalsaPCR master mix containing the labeled forward primer and the unlabeled reverse primer. PCR amplificationinvolved35cyclesof 94 C for 30 seconds, 58 C for 30 seconds, and 72 C for 30 seconds, followed by 72 C for 4 minutes. The resulting MLPA amplicons were analyzed by fragment analysis using an ABI 3130 XL capillary electrophoresis system (Applied Biosystems, Foster City, CA). For fragment analysis, 0.5 mLo fP C R amplicon was mixed with 19 mL of Hi-di Formamide and 0.5 mL Genescan-400 HD ROX size standard (Applied Biosystems). The mixture was incubated for 3 minutes at 95 C and analyzed.
Statistical Analysis
Samples were classified using a linear predictor score and a Bayesian predictor, assuming that the distribution of the scores within the different groups was normal, allowing the estimation of the probability for each case of belonging to one of the three DLBCL subtypes. Scaling factors were applied to balance the overweighting of the most highly expressed genes. To account for these differences in expression ranges, the t statistic that was used for the gene-specificcoefficients was further divided by the mean expression of the corresponding genes in the training series. This interpretation of the results was made using dedicated homemade software (The RT-MLPA interface; https://bioinfo. calym.org/RTMLPA, registration required, last accessed June 27, 2017) that handles the entire analytic process, with a 90% confidence threshold to classify a sample. The Wilcoxon rank sum test was used to compare the expression of the different markers in the different subtypes.
Results

Gene Selection
Twenty-one genetic markers were included in the RT-MLPA assay. Eleven genes were selected from the literature to discriminate ABC from GCB cases (ITPKB, LMO2, MAML3, MME, MYBL1, NEK6 for GCB; and IRF4, FOXP1, IGHM, TNFRSF13B, LIMD1 for ABC) and three to identify PMBLs (FCER2 encoding CD23, TNFRSF8 encoding CD30, and MAL). 1,4,18e20 The EBER1 mRNA (EBV-encoded small nuclear early region) was included to assess the EBV infection status. Five additional markers were included as follows: CCND1 overexpressed in mantle cell lymphoma, CRBN targeted by the immunomodulatory drugs lenalidomide and pomalidomide, 21 MYC and CD5 whose expression is associated with a poor outcome, and MS4A1 encoding the CD20 receptor. Finally, two RT-MLPA probes were designed to examine the MYD88 L265P hot-spot mutation status (Supplemental Figure S1 ). Representative RT-MLPA profiles of ABC, GCB, and PMBL cases are presented in Figure 1 .
RT-MLPA Robustness
The RT-MLPA assay was applied to 150 RNA samples extracted from archival paraffin-embedded biopsies from the GHEDI study. Fourteen biopsies had been treated with an alcohol, formalin, acetic acid (AFA) fixative, 4 with a Bouin fixative, and 91 with formaldehyde. No information was available for the remaining cases obtained from different institutions. The median RNA concentration was 21 ng/mL (range, 4 to 94 ng/mL). Interpretable profiles were obtained for 143 of 150 cases (95.3%), including 13 of 14 AFA-and 3 of 4 Bouin-fixed samples (Supplemental Figures S2eS5) , confirming the robustness of the RT-MLPA procedure despite the heterogeneity of the fixatives.
Class Prediction
The reference cell-of-origin classification was established by unsupervised hierarchical analysis (complete distance, Ward agglomeration) using HGU133 þ 2.0 Affymetrix GeneChip arrays expression data obtained from frozen biopsies from the 150 cases of the GHEDI study (GEO, GSE87371). For this analysis, 56 GCB/ABC and 39 DLBCL/PMBL discriminant genes were selected from the literature ( Supplemental Table S2 ). 3, 4, 9 Three clusters were delineated, allowing the identification of 63 ABC, 55 GCB, and 15 molecular PMBL (m-PMBL) cases (42%, 37%, and 10% of cases, respectively) ( Figure 2 ). Seventeen samples (11%) could not be classified into any recognizable cluster and were considered unclassified. For validation, the same gene expression data set was analyzed using the Wright's algorithm as previously described. 3 Excluding the 15 PMBL cases, which, as expected, were classified within the GCB subtype, the two methods reached an agreement of 85.2%, confirming the validity of the hierarchical clustering analysis. In addition, next-generation sequencing (NGS) data indicated that 13 of the 15 PMBL cases identified by hierarchical clustering presented a mutation of the STAT6 gene, particularly enriched in this lymphoma subtype. 22 As shown in Figure 3 , principal component analysis of the RT-MLPA data for the 143 analyzable cases of the GHEDI cohort delineated three subgroups of genes: IGHM, FOXP1, TNFRSF13B, and LIMD1 (ABC DLBCLs signature); CD30, MAL, and CD23 (PMBL signature); and ITPKB, NEK6, LMO2, MAML3, MYBL1, and MME (GCB DLBCLs signature). As expected, IRF4, which is expressed in most ABC DLBCLs and PMBLs, clearly distinguished those lymphoma from GCB cases.
To assign each case into one of these three subtypes, a linear predictor score method was applied to train two consecutive Bayesian predictors. The first was built to identify PMBL cases and the second to discriminate GCB from ABC cases (Figure 4 ). The first Bayesian predictor was trained using 70 GHEDI samples obtained by retaining all interpretable m-PMBL (n Z 13) and by randomly selecting half of the GCB (n Z 26) and half of the ABC (n Z 31) cases ( Figure 5 ). As expected, the three CD23, CD30, and MAL genes were significantly overexpressed in PMBL cases in this series ( Figure 6 ,A eC). IGHM expression was also significantly lower in these lymphoma, which most often lack immunoglobulin expression ( Figure 6D ). Furthermore, other markers showed discriminant variations, including LMO2 and NEK6, two GCB markers, and TNFRSF13B and FOXP1, two ABC markers.
In this training series, this first predictor correctly identified 12 of 13 m-PMBL cases (92.3%), and none of the 57 non-PMBL biopsies were incorrectly assigned to this subtype ( Figure 5A ). For validation, the same predictor was next applied to an independent series of 96 cases, which included all remaining GCB (n Z 26) and ABC (n Z 32) cases of the GHEDI cohort, complete with 38 histologic PMBLs. In this independent cohort, 29 histologic PMBLs were classified as PMBLs (76.3%), seven cases were considered unclassified (18.4%), and two cases were classified as non-PMBL (5.3%). Only one non-PMBL case of the GHEDI cohort (classified in the GCB subgroup by hierarchical clustering) was misclassified into this molecular subtype ( Figure 5B) .
A second Bayesian predictor was built to discriminate ABC from GCB cases. Again, a training series was obtained by randomly selecting half of the GCB (n Z 26) and half of the ABC (n Z 31) cases of the GHEDI cohort. In this series, 52 cases (91.2%) classified within the expected subtypes (28 ABC, 24 GCB) and five samples (3 ABC, 2 GCB) were considered unclassified ( Figure 7A ).
As expected, the expression of ITPKB, LMO2, MAML3, NEK6, and MYBL1 were overexpressed in GCB cases (Figure 8,A eF) , whereas FOXP1, IRF4, LIMD1, and TNFRSF13B was significantly associated with the ABC subtype (Figure 8,G eK) . To validate this algorithm, a second independent cohort was analyzed, which comprised all remaining GCB (n Z 26) and ABC (n Z 32) cases. Here, 50 cases classified within the expected subtype (27 ABC and 23 GCB; 86.2%), 6 were considered unclassified (4 ABC and 2 GCB; 10.3%) and only 2 were misclassified (1 ABC and 1 GCB; 3.4%) ( Figure 7B) .
Overall, the RT-MLPA assay correctly assigned 85.0% of the ABC, GCB, and m-PMBL cases of the GHEDI cohort into the expected subtypes [55 of 63 ABC (87.3%); 46 of 55 GCB (83.6%); and 12 of 15 m-PMBL (80%)] ( Table 2 ). Seven RT-MLPA profiles (4.7%) were considered uninterpretable, 11 cases (8.3%) were considered unclassified, and 4 cases (3.1%) were misclassified, with 2 GCB classified as ABC and PMBL, 1ABCclassified as GCB, and 1 m-PMBL classified as GCB. Interestingly, the only ABC case misclassified as GCB by RT-MLPA exhibited an EZH2 Y644 mutation identified by NGS. The reason for this discrepancy was unknown, but a strong association between this mutation and the GCB GEP signature has been shown in previous studies. 17 By comparison, the Hans IHC algorithm correctly assigned 78.8% of the ABC and GCB cases of the GHEDI cohort [53 of 63 ABC (84.1%) and 40 of 55 GCB (72.7%) cases] ( Table 3) . As expected, a majority of m-PMBL cases (10 of 14; 71.4%) were classified within the non-GCB subtype by IHC, due to a dominant CD10-negative, BCL6positive, MUM1-positive immunophenotype. Finally, all 16 unclassified cases classified into the non-GCB subgroup using the Hans algorithm, and nine cases where considered uninterpretable because of a lack of informativity for at least one IHC marker.
MYD88 L265P Mutation Detection
We next verified the capacity of the RT-MLPA assay to correctly detect the MYD88 L265P mutation. Ten positive control cases from the Center Henri Becquerel, where the mutation had been previously detected by Sanger sequencing, were tested. As shown in Figure 9Aa Figures S6eS8, all showed the expected signal. Sixteen MYD88 L265P mutations were also detected in the GHEDI cohort. Fifteen had been previously identified by NGS with allele frequencies ranging from 19.8% to 82.1% (median, 46.2%), confirming the sensitivity of the assay. The last mutated case of the GHEDI cohort was not analyzed by NGS because of a lack of available material. Importantly, no false-positive calls occurred in the 125 negative cases of the GHEDI cohort previously analyzed by NGS, confirming the specificity of the assay (positive predictive value and negative predictive value of 100%). Furthermore, as expected, all 26 mutated cases were classified within the ABC subtype using the Bayesian predictors, which does not take the presence of this marker into account for the classification.
EBV Infection Status Evaluation
We next verified the ability of the RT-MLPA assay to assess the EBV infection status. For the retrospective 10 EBVpositive and 10 EBV-negative control samples from the Center Henri Becquerel previously analyzed by ISH were tested. As shown in Figure 9B and Supplemental Figures S9eS11, all showed the expected EBER signal. Only one EBV-positive DLBCL case was identified in the GHEDI cohort, and it was considered unclassified by the RT-MLPA predictors, the hierarchical clustering approach, and the Wright's algorithm.
Discussion
In recent years, major advances have been made in the understanding of the heterogeneity of DLBCLs. According to the 2016 revision of the World Health Organization classification of lymphoid neoplasms, the different subtypes should now be identified at diagnosis. IHC algorithms are considered acceptable, but GEP-based methods are seen as promising alternatives. There is therefore an increasing need for accurate diagnostic tools that could be integrated into the diagnostic workflow.
The new RT-MLPA classifier we developed was trained using paraffin-embedded samples as available at most institutions. Interpretable gene expression profiles were obtained for 143 of 150 of the archival samples (95.3%) of the GHEDI cohort, demonstrating its robustness. Its capacity to provide reliable results even with Bouin-or AFA-treated biopsies, from which RNA extraction is generally considered highly challenging, confirms its resistance to RNA degradation. This advantage, which results from the very short RNA fragments required for the correct hybridization of the RT-MLPA probes, could prove particularly useful in daily practice. The concordance of the RT-MLPA results with the gold standard Affymetrix classification compares favorably with other diagnostic methods such as immunochemistry. More specifically, and as could be verified on the GHEDI cohort, gene expressionb a s e da s s a yc a nd i r e c t l yi d e ntify ABC cases through the expression of specific markers and do not attribute the samples by default into a non-GCB category when no GCB markers are detected. Its capacity to interrogate the MYD88 L265P mutation and the EBV infection status as well as other important markers such as MS4A1 (CD20) or CD30, which are not systematically addressed by IHC, could also be particularly useful for therapeutic decision. It also appears as an interesting tool to discriminate PMBL from other DLBCLs, which could soon benefit from targeted therapies.
The diagnosis of PMBL is usually evoked when patients present with mediastinal involvement. However, the diagnosis of these tumors is often challenging, and recent studies have suggested that not all cases show this typical presentation. 13 When applied to these tumors, the Hans IHC algorithm usually returns a non-GCB classification because of a predominant CD10 À BCL6 þ MUM1 immunophenotype. By contrast, the RT-MLPA assay allows a systematic evaluation of three important PMBL markers, CD30, CD23,andMAL,aswellas MME (which encodes CD10, usually negative in these pathologic processes), IGHM (usually negative), and IRF4 (usually positive). It could thus be particularly useful to identify these cases with atypical clinical presentations. It can also differentiate PMBLs from other DLBCLs that may, by chance, originate in the mediastinal region. This probably occurred for case CHB_1570, initially diagnosed as a PMBL because of its mediastinal localization, but whichclearlyshowedanABCgene expression profile.
Our assay also correctly identified all control EBV-positive cases and one additional case in the GHEDI cohort. Furthermore, applied to the 23 last consecutive cases who presented in our institution, RT-MLPA and EBV-ISH showed a 100% agreement, with 2 positive and 21 negative cases identified (data not shown). EBV-positive DLBCL of the elderly was introduced in the 2008 World Health Organization classification of lymphoid neoplasms as a provisional entity restricted to patients older than 50 years and is in general associated with a poor prognosis. 23 However, a recent study comparing older and younger patients reported no significant clinical differences, 24 leading to the extension of this subtype to all ages in the 2016 revision of the classification. Its prevalence is estimated between 5% and 15% of all DLBCL cases, 23 but because EBV testing is not systematically performed at diagnosis, many cases are probably managed as EBV-negative DLBCLs. Still, new promising therapeutic approaches are currently under evaluation for these diseases, including antiviral therapy in combination with EBV lytic phase induction, 25 EBV specific cytotoxic T lymphocytes 26 or chimeric antigen receptor T cells. The RT-MLPA assay could thus allow a more systematic identification of those patients.
Among the other therapeutic markers included in the assay, CD30 is a therapeutic target. 27e29 Likewise, cereblon is a direct target of lenalidomide and pomalidomide, two drugs currently under clinical evaluation for these tumors. 21 The systematic evaluation of these markers by RT-MLPA could thus be particularly useful in prospective clinical trials testing these new therapies. In addition, the RT-MLPA approach proved to be particularly efficient in detecting the MYD88 L265P mutation, one of the most common genetic abnormalities in ABC DLBCLs, and may be predictive of ibrutinib sensitivity. 30, 31 Conclusions RT-MLPA appears as an efficient, rapid, and cost-effective alternative to the current methods used in the clinic to establish the cell of origin classification of DLBCLs. In contrast to other technologic approaches such as RNAseq or Nanostring technologies, its implementation requires only common laboratory equipment, that is, a thermal cycler and a capillary genetic analyzer, and does not necessitate the acquisition of any specialized platform. By allowing the identification of the three major DLBCL subtypes and a simultaneous evaluation of multiple prognostic and theranostic markers and therapeutic targets, RT-MLPA could contribute to a more efficient management of these aggressive tumors in both clinical trials and daily practice.
